Essential Pharma Announces the Acquisition of HALDOL®
Essential Pharma Announces the Acquisition of HALDOL® HALDOL® is a first-generation ‘typical’ antipsychotic for the treatment of schizophrenia and some other psychiatric conditions The acquisition ensures access to this much-needed antipsychotic for patients and further strengthens Essential Pharma’s portfolio of specialist medicines across key therapeutic areas, particularly in CNS and GI domains Zug, Switzerland – […]